<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26037">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767804</url>
  </required_header>
  <id_info>
    <org_study_id>X396-CLI-301</org_study_id>
    <nct_id>NCT02767804</nct_id>
  </id_info>
  <brief_title>eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients</brief_title>
  <official_title>Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xcovery Holding Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xcovery Holding Company, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the efficacy and safety of X-396
      (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that
      have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with
      ALK-positive NSCLC that have received up to 1 prior chemotherapy regimen and no prior ALK
      tyrosine kinase inhibitor (TKI), to obtain additional pharmacokinetic (PK) data from sparse
      PK sampling, to compare the quality of life (QoL) in patients receiving X-396 vs.
      crizotinib, to evaluate the status of exploratory biomarkers and correlate with clinical
      outcome, and to obtain germline DNA samples for possible pharmacogenetic analysis in the
      event that outliers with respect to efficacy, tolerability/safety, or exposure are
      identified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) as assessed by independent radiology review based on RECIST v. 1.1 criteria</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) based on independent radiology review</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS based on investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR based on investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response based on independent radiology review</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response based on investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response based on independent radiology review</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response based on investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>CNS response rate based on independent radiology review</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CNS response rate based on investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to CNS progression</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients with adverse events</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported time to deterioration (TTD) as measured by EORTC C30/LC13 QoL questionnaire</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported TTD as measured by Lung Cancer Symptom Scale (LCSS)</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported health-related quality of life (HRQoL) as measured by EORTC C30/LC13 QoL questionnaire</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported HRQoL as measured by LCSS</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentrations (Cmax) at participating sites</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentrations (Cmin) at participating sites</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>X-396 (ensartinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>crizotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>X-396 (ensartinib)</intervention_name>
    <description>oral ALK inhibitor</description>
    <arm_group_label>X-396 (ensartinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizotinib</intervention_name>
    <description>oral ALK inhibitor</description>
    <arm_group_label>crizotinib</arm_group_label>
    <other_name>Xalkori</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage
             IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is
             ALK-positive. Patients may have received up to 1 prior chemotherapy regimen, which
             may also include maintenance therapy.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2.

          -  Life expectancy of at least 12 weeks.

          -  Ability to swallow and retain oral medication.

          -  Adequate organ system function.

          -  Brain metastases allowed if asymptomatic at study baseline.

          -  Men willing to use adequate contraceptive measures.

          -  Women who are not of child-bearing potential, and women of child-bearing potential
             who agree to use adequate contraceptive measures and who have a negative serum or
             urine pregnancy test.

          -  Patients must be at least 18 years of age.

          -  Patients must have measurable disease per RECIST v. 1.1.

          -  Patients must be ALK-positive by IHC.

          -  Willingness and ability to comply with the trial and follow-up procedures.

          -  Ability to understand the nature of this trial and give written informed consent.

        Exclusion Criteria:

          -  Patients that have previously received an ALK TKI, and patients currently receiving
             cancer therapy.

          -  Use of an investigational drug within 21 days prior to the first dose of study drug.

          -  Any chemotherapy within 4 weeks, or major surgery or radiotherapy within the last 14
             days.

          -  Patients with primary CNS tumors and leptomeningeal disease are ineligible.

          -  Patients with a previous malignancy within the past 3 years.

          -  Concomitant use of drugs with a risk of causing Torsades de Pointes. -Concomitant use
             of herbal medications.

          -  Patients receiving strong CYP3A inhibitors or inducers.

          -  Women who are pregnant or breastfeeding.

          -  Presence of active gastrointestinal (GI) disease or other condition that will
             interfere significantly with the absorption, distribution, metabolism, or excretion
             of study medications.

          -  Clinically significant cardiovascular disease.

          -  Patients who are immunosuppressed (including known HIV infection), have a serious
             active infection at the time of treatment, have interstitial lung
             disease/pneumonitis, or have any serious underlying medical condition that would
             impair the ability of the patient to receive protocol treatment.

          -  Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.

          -  Concurrent condition that in the investigator's opinion would jeopardize compliance
             with the protocol or would impart excessive risk associated with study participation
             that would make it inappropriate for the patient to be enrolled.

          -  Inability or unwillingness to comply with study and/or follow-up procedures outlined
             in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jolee D. Holt, RN</last_name>
    <phone>918-899-1012</phone>
    <email>jholt@optimalsites.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Holly Hoefer, MSHC</last_name>
    <phone>918-899-1012</phone>
    <email>optimalcommunity@optimalsites.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Helen Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milijana Ugrenovic-Petrovic</last_name>
      <phone>813-745-2010</phone>
      <email>milijana.ugrenovic@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Alberto Chiappori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Pearce</last_name>
      <phone>313-916-1784</phone>
      <email>tpearce1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Igor Rybkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian McGowan</last_name>
      <phone>314-747-7569</phone>
      <email>irmcgowan@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Saiama Waqar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology-Oncology Associates, PC</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chu, MD</last_name>
      <phone>631-751-3000</phone>
      <email>dchu@nycancer.com</email>
    </contact>
    <investigator>
      <last_name>David Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Fisher</last_name>
      <phone>503-215-2613</phone>
      <email>Brenda.fisher@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rachel E. Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Pavilion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Dennison</last_name>
      <phone>412-623-4868</phone>
    </contact>
    <contact_backup>
      <last_name>dennisonr@upmc.edu</last_name>
    </contact_backup>
    <investigator>
      <last_name>Liza Villaruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Combs</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Leora Horn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Banks</last_name>
      <phone>703-970-6553</phone>
      <email>Stacey.banks@inova.org</email>
    </contact>
    <investigator>
      <last_name>Joan H. Schiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Regional Cancer System</name>
      <address>
        <city>Lacey</city>
        <state>Washington</state>
        <zip>98503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deidre Dillon, RN</last_name>
      <phone>360-754-3934</phone>
    </contact>
    <investigator>
      <last_name>Xingwei D. Sui, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology Research Unit</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqui McBurnie</last_name>
      <phone>612 6064 1508</phone>
      <email>jmcburnie@bordermedonc.com.au</email>
    </contact>
    <investigator>
      <last_name>Craig Underhill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilie Collet</last_name>
      <phone>32 81423028</phone>
      <email>emilie.collet@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Sebahat Ocak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Paulino, RN</last_name>
      <phone>780-432-8359</phone>
      <email>jennifer.paulino@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Anil Joy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infirmière recherche Clinique, IUCPQ</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte Fortin</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>2639</phone_ext>
      <email>brigitte.fortin@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Lise Tremblay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vítkovická Nemocnice , a.s.</name>
      <address>
        <city>Ostrava-Vitkovice</city>
        <zip>70384</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaromir Roubec, MD</last_name>
      <phone>420 565 633 400</phone>
      <email>jaromir.roubec@vtn.agel.cz</email>
    </contact>
    <investigator>
      <last_name>Jaromir Roubec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vítkovická Nemocnice , a.s.</name>
      <address>
        <city>Ostrava</city>
        <zip>70384</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaromir Roubec, MD</last_name>
      <phone>+420 565 633</phone>
      <email>jaromir.roubec@vtn.agel.cz</email>
    </contact>
    <investigator>
      <last_name>Jaromir Roubec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Pleši s.r.o.</name>
      <address>
        <city>Plesice</city>
        <zip>26204</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Vydra, MD</last_name>
      <phone>420318541502</phone>
      <email>vydra@naplesi.cz</email>
    </contact>
    <investigator>
      <last_name>Jan Vydra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krajská zdravotní, a.s., Masarykova nemocnice</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Doležal</last_name>
      <phone>420477113488</phone>
      <email>daniel.dolezal@kzcr.eu</email>
    </contact>
    <investigator>
      <last_name>Pavel Reiterer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Morvan CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles Robinet</last_name>
      <phone>02 98 22 33 95</phone>
      <email>gilles.robinet@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Renaudd Descourt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre GF Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anais Grilo</last_name>
      <phone>03 80 73 77 56</phone>
      <email>agrilo@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Coudert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Wasielewski</last_name>
      <phone>333.20.44.59.62</phone>
      <phone_ext>31105</phone_ext>
      <email>eric.wasielewski@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Alexis Cortot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Gestin-Boyer, PhD</last_name>
      <phone>04.67.61.25.08</phone>
      <email>Christine.Gestin-Boyer@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Quantin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilie Vallée</last_name>
      <phone>+331 42 38 51 10</phone>
      <email>emilie.vallee-willien@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Ludovic Doucet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mélanie Pringent</last_name>
      <phone>33 2 99 28 97 95</phone>
    </contact>
    <investigator>
      <last_name>Hervé Lena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest (ICO)</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucie Labarre</last_name>
      <phone>+33 2 40 67 99 00</phone>
      <email>lucie.labarre@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine Hiret, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nouvel Hospital Civil de Stasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Koukeb Malki-Rouguieg, PhD</last_name>
      <phone>03 69 55 16 75</phone>
      <email>koukeb.malki-rouguieg@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Quiox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>D-12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maike De Wit, MD</last_name>
      <phone>+49 30130142251</phone>
      <email>maike.dewit@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Maike De Wit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lungen Clinic Grosshansdorf</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Reck, MD</last_name>
      <phone>0049 4102 601 2100</phone>
      <email>m.reck@lungenclinic.de</email>
    </contact>
    <investigator>
      <last_name>Martin Reck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Löwenstein gGmbH Med. Klinik II Onkologie</name>
      <address>
        <city>Lowenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jurgen Fischer, MD</last_name>
      <phone>49(0)713015 6226</phone>
      <email>juergen.fischer@klinik-loewenstein.de</email>
    </contact>
    <investigator>
      <last_name>Jurgen Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Hämatologie und Onkologie Stolberg</name>
      <address>
        <city>Stolberg</city>
        <zip>D-52222</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Groschek, M</last_name>
      <phone>+49 24027668829</phone>
      <email>praxis@onkologie-stolberg.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Groschek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Centre</name>
      <address>
        <city>Be'er Sheva`</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ilona Hanukov</last_name>
      <phone>97286244127</phone>
      <email>IlonaH@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Julia Dudnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arfa Gilad</last_name>
      <phone>972 2 6776760</phone>
      <email>gilada@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Hovav Nechushtan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center Institute of Oncology, Davidoff Center</name>
      <address>
        <city>Petah Tiqva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dana Bromberg</last_name>
      <phone>972 39378086</phone>
      <email>danabr1@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Dudnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico CRO Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Da Ros</last_name>
      <phone>+39 0434 659079</phone>
      <email>vdaros@cro.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Bearz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Salutis</name>
      <address>
        <city>Legnago</city>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Pigozzi</last_name>
      <phone>+390442622801</phone>
      <email>oncologia.medica.leg@aulsslegnago.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Bonetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Ragazzini, MD</last_name>
      <phone>+39 0543 739268</phone>
      <email>angela.ragazzini@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Angelo Delmonte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IEO Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Boselli</last_name>
      <phone>39 02 94372730</phone>
      <email>sabrina.boselli@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Filippo de Marinis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Operativo Studi Clinici S.C.Oncologia Medica</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberta Matocci</last_name>
      <phone>+39 0755784099</phone>
      <email>roberta.matocci@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giulio Metro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica</name>
      <address>
        <city>Revenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Dazzi, MD</last_name>
      <phone>+39 0544285778</phone>
      <email>claudio.dazzi@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Dazzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre (MUMC)</name>
      <address>
        <city>Maastricht</city>
        <zip>6229HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carola Schurink</last_name>
      <phone>+31 43-3871049</phone>
      <email>trials.longoncologie@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>AMC Dingemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Egaña</last_name>
      <phone>0034 948 296696</phone>
      <email>megana@unav.es</email>
    </contact>
    <investigator>
      <last_name>Jose Lopez-Picazo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Taus, MD</last_name>
      <phone>34932483137</phone>
      <email>ataus@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Alvaro Taus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laia Lavernia Rosell</last_name>
      <phone>+34 93 553 72</phone>
      <email>llavernia@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Margarita Majem Tarruella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Alonso</last_name>
      <phone>34 935460135</phone>
      <email>talonso@oncorosell.com</email>
    </contact>
    <investigator>
      <last_name>Santiago Viteri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Beltrán</last_name>
      <phone>34 93 489 4374</phone>
      <email>mbeltran@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Enriqueta Felip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Tauli'</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Garcia Ruiz</last_name>
      <phone>+34 93 724 00 84</phone>
      <email>jgarciar@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Yolanda Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona - Hospital Doctor Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Begoña Martin</last_name>
      <phone>+34 972 22 58 28</phone>
      <phone_ext>4028</phone_ext>
      <email>bmartin@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Joaquim Bosch-Barrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Ltatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Ayuga</last_name>
      <phone>+34 871 202 000</phone>
      <phone_ext>1629</phone_ext>
      <email>sayuga@hsll.es</email>
    </contact>
    <investigator>
      <last_name>Pilar Mut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackwood</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Gratix</last_name>
      <phone>01253 953744</phone>
      <email>karen.gratrix@bfwhospitals.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sin Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Morley</last_name>
      <phone>+44 (0)117 414 8114</phone>
      <email>anna.morley@nbt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Alfredo Addeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings Mill hospital</name>
      <address>
        <city>Nottinghamshire</city>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sue Smith</last_name>
      <phone>01623 672 440</phone>
      <email>susan.smith1@sfh-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ivo Hennig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>April 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK-positive NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
